JP2022512781A5 - - Google Patents

Info

Publication number
JP2022512781A5
JP2022512781A5 JP2021521816A JP2021521816A JP2022512781A5 JP 2022512781 A5 JP2022512781 A5 JP 2022512781A5 JP 2021521816 A JP2021521816 A JP 2021521816A JP 2021521816 A JP2021521816 A JP 2021521816A JP 2022512781 A5 JP2022512781 A5 JP 2022512781A5
Authority
JP
Japan
Prior art keywords
patient
antibody
hematopoietic stem
stem cells
immunosuppressant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021521816A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512781A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/058973 external-priority patent/WO2020092655A1/en
Publication of JP2022512781A publication Critical patent/JP2022512781A/ja
Publication of JP2022512781A5 publication Critical patent/JP2022512781A5/ja
Priority to JP2024213792A priority Critical patent/JP2025038016A/ja
Pending legal-status Critical Current

Links

JP2021521816A 2018-10-30 2019-10-30 同種造血幹細胞移植の方法 Pending JP2022512781A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024213792A JP2025038016A (ja) 2018-10-30 2024-12-06 同種異系の造血幹細胞移植の方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862752828P 2018-10-30 2018-10-30
US62/752,828 2018-10-30
US201862773873P 2018-11-30 2018-11-30
US62/773,873 2018-11-30
US201962882362P 2019-08-02 2019-08-02
US62/882,362 2019-08-02
PCT/US2019/058973 WO2020092655A1 (en) 2018-10-30 2019-10-30 Methods for allogeneic hematopoietic stem cell transplantation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024213792A Division JP2025038016A (ja) 2018-10-30 2024-12-06 同種異系の造血幹細胞移植の方法

Publications (2)

Publication Number Publication Date
JP2022512781A JP2022512781A (ja) 2022-02-07
JP2022512781A5 true JP2022512781A5 (OSRAM) 2022-11-07

Family

ID=70462151

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021521816A Pending JP2022512781A (ja) 2018-10-30 2019-10-30 同種造血幹細胞移植の方法
JP2024213792A Pending JP2025038016A (ja) 2018-10-30 2024-12-06 同種異系の造血幹細胞移植の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024213792A Pending JP2025038016A (ja) 2018-10-30 2024-12-06 同種異系の造血幹細胞移植の方法

Country Status (12)

Country Link
US (1) US20210379195A1 (OSRAM)
EP (1) EP3877415A4 (OSRAM)
JP (2) JP2022512781A (OSRAM)
KR (1) KR20210086683A (OSRAM)
CN (1) CN113301923A (OSRAM)
AU (1) AU2019374055A1 (OSRAM)
BR (1) BR112021008437A2 (OSRAM)
CA (1) CA3117366A1 (OSRAM)
IL (1) IL282637A (OSRAM)
MX (1) MX2021004579A (OSRAM)
SG (1) SG11202104084WA (OSRAM)
WO (1) WO2020092655A1 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190320633A1 (en) 2016-11-30 2019-10-24 The Jackson Laboratory Humanized mouse model with improved human innate immune cell development
US10882915B2 (en) 2017-10-24 2021-01-05 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
AU2019265019B2 (en) 2018-05-11 2025-11-06 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
EP3958899A4 (en) * 2019-04-24 2023-08-02 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODY-DRUG CONJUGATES AND THEIR USES
EP3959242A4 (en) * 2019-04-24 2023-09-13 Magenta Therapeutics, Inc. ANTRACYCLINE ANTIBODY-DRUG CONJUGATES AND THEIR USES
WO2020219775A1 (en) * 2019-04-24 2020-10-29 Magenta Therapeutics, Inc. Anti-cd117 antibody-drug conjugates and uses thereof
GB202015226D0 (en) * 2020-09-25 2020-11-11 Adc Therapeutics S A Pyrrol obenzodiazepine-antibody conugates and uses thereof
US12496303B2 (en) * 2020-10-19 2025-12-16 Washington University Conditioning agents for use in allogeneic hematopoietic stem cell transplantation
EP4433512A4 (en) 2021-11-19 2025-12-31 Univ Pennsylvania Genetically modified pan-leukocyte-specific CD45 antigen to facilitate T-lymphocyte therapy
CN118647724A (zh) * 2021-12-22 2024-09-13 杰克逊实验室 人源化小鼠模型
CA3240875A1 (en) * 2021-12-23 2023-06-29 Stefanie Urlinger Discernible cell surface protein variants of cd45 for use in cell therapy
US20250171536A1 (en) * 2022-03-01 2025-05-29 CSL Innovation Pty Ltd Methods of Bone Marrow Conditioning
JP2025510189A (ja) * 2022-03-24 2025-04-14 アクティニウム ファーマシューティカルズ インコーポレイテッド ヒト化抗ｃｄ４５抗体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE439137T1 (de) * 1997-11-14 2009-08-15 Gen Hospital Corp Behandlung von hämatologischen störungen
CA2844109C (en) * 2010-08-18 2018-11-06 Theresa Deisher Compositions and methods to inhibit stem cell binding to active germinal centers in lymphatic tissues
WO2016164502A1 (en) * 2015-04-06 2016-10-13 President And Fellows Of Harvard College Compositions and methods for non-myeloablative conditioning
KR20230082055A (ko) * 2016-06-17 2023-06-08 마젠타 테라퓨틱스 인코포레이티드 세포의 고갈을 위한 조성물 및 방법
MX2018015684A (es) * 2016-06-17 2019-08-29 Magenta Therapeutics Inc Composiciones y metodos para el agotamiento de celulas cd117.
JP7669269B2 (ja) * 2018-10-30 2025-04-28 ブイオーアール バイオファーマ インコーポレーテッド 抗－ｃｄ４５抗体及びそのコンジュゲート
WO2020219959A1 (en) * 2019-04-24 2020-10-29 Magenta Therapeutics, Inc. Anti-cd45 antibody drug conjugates and uses thereof
SG11202113331QA (en) * 2019-06-04 2021-12-30 Magenta Therapeutics Inc Methods and compositions for treating autoimmune diseases
JP7716399B2 (ja) * 2019-11-01 2025-07-31 ブイオーアール バイオファーマ インコーポレーテッド 抗－ｃｄ４５抗体及びそのコンジュゲート

Similar Documents

Publication Publication Date Title
Liu et al. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids.
US20230110128A1 (en) Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
JP2020183429A (ja) 有効性の改善および毒性の減少のための、抗体およびｓｎ−３８からなるイムノコンジュゲートの投薬
US20260034232A1 (en) Near Infrared Photoimmunotherapy
CN109589336B (zh) 用于t细胞免疫疗法的组合及其用途
RU2016111137A (ru) Сконструированные конъюгаты против dll3 и способы применения
US20210379195A1 (en) Methods for allogeneic hematopoietic stem cell transplantation
AU2010310577A1 (en) Novel dosing regimen and method of treatment
CN102271711B (zh) 每种维持移植物抗肿瘤效应的免疫重建促进剂或感染预防剂
JP2019517505A5 (OSRAM)
CN118356508A (zh) 使用抗体-药物缀合物调节免疫应答
Valent et al. Cell-based and antibody-mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: perspectives and open issues
JP2019511199A (ja) 新規の抗ｕｐｋ１ｂ抗体及び使用方法
JP2019525727A (ja) 新規の抗ｔｎｆｒｓｆ２１抗体及び使用方法
JP2023514347A5 (OSRAM)
Kato et al. Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia
CN114173820A (zh) 用于治疗自身免疫疾病的方法和组合物
Ahmed et al. The potential of antibody-drug conjugates for effective therapy in diffuse large B-cell lymphoma
US20060051355A1 (en) Methods and means for the treatment of immune-related diseases
ES2213355T3 (es) Cocteles de inmunotoxinas para el tratamiento de enfermedades de origen inmunologico.
Routledge Belantamab mafodotin. Antibody-drug conjugate targeting B-cell maturation antigen (BCMA), Treatment of multiple myeloma
BOSTRÖM et al. Monoclonal antibodies in transplantation: prophylaxis and treatment of
Fishwild Efficacy of an anti-CD5-ricin A chain immunoconjugate in an improved human peripheral blood lymphocyte--reconstituted severe combined immunodeficient mouse model
NZ736728A (en) Cd123 antibodies and conjugates thereof
Jurcic Antibody-Based Therapy of Myeloid Leukemia